NEW STUDY : HYDROXYCHLOROQUINE WAS SAVING LIVES WHEN THEY BANNED IT
Just released a retrospective study from France (30,000+ patients) has found that HCQ + Azithromycin was REDUCING DEATHS by 71% when given early and by 45% when given in hospital – before they banned it.
If the world had followed the science on HCQ, there would have been no need for lockdowns, no economic damage, no printing of money, a huge reduction in covid deaths, and no vaccine injuries.
Further, those that fabricated studies to discredit HCQ (Surgishere) and those that ran studies designed to fail (Oxford) by overdosing – SHOULD BE PLACED UNDER ARREST
Objective To estimate the comparative effectiveness of combination therapy with hydroxychloroquine (HCQ) and azithromycin for coronavirus disease 2019 (COVID-19)- related death based on a large monocentric cohort independent of investigators’ putative biases in a real-world setting.
Design Retrospective monocentric cohort study, with comprehensive data collection authenticated by an external bailiff and death reports from a national database (French National Death Registry).
Setting Institut Hospitalo-Universitaire Méditerranée Infection Center in Marseille, France.
Participants All adults older than 18 years with PCR-proven COVID-19 who were treated directly in our centre between 2 March 2020 and 31 December 2021 and did not refuse the use of their data.
Interventions HCQ and azithromycin (HCQ-AZ) as a reference treatment were compared to other regimens containing HCQ, ivermectin and azithromycin alone, combined, or none of these three drugs. The effect of vaccination was also evaluated.
Main outcome measures 6-week all-cause mortality. Multivariable logistic regression estimated treatment effectiveness with adjustments for age, sex, comorbidities, vaccination, period of infection or virus variant, and outpatient or inpatient care.
Results Total 30,423 COVID-19 patients were analysed (86 refused the analysis of their data) including 30,202 with available treatment data, and 535 died (1.77%). All-cause mortality was very low among patients < 50 years (8/15,925 (0.05%)) and among outpatients treated with HCQ-AZ (21 deaths out of 21,135 (0.1%), never exceeding 0.2% regardless of epidemic period). HCQ-AZ treatment was associated with a significantly lower mortality rate than no HCQ-AZ after adjustment for sex, age, period and patient care setting (adjusted OR (aOR) 95% confidence interval (CI) 0.55, 0.45-0.68). The effect was greater among outpatients (71% death protection rate) than among inpatients (45%). In a subset of 16,063 patients with available comorbidities and vaccinations status, obesity (2.01, 1.23-3.29), chronic respiratory disease (2.93, 1.29-6.64), and immunodeficiency (4.01, 1.69-9.50), on the one hand, and vaccination (0.29, 0.12-0.67) and HCQ-AZ treatment (0.47, 0.29-0.76), on the other hand, were independent factors associated with mortality. HCQ, alone or in any association, was associated with significant protection from death among outpatients (0.41, 0.21-0.79) and inpatients (0.59, 0.47-0.73).
Conclusions HCQ prescribed early or late protects in part from COVID-19-related death. During pandemic health crises, financial stakes are enormous. Authentication of the data by an independent external judicial officer should be required. Public sharing of anonymized databases, ensuring their verifiability, should be mandatory in this context to avoid fake publications.
Competing Interest Statement
All authors have completed the Unified Competing Interest form (available on request from the corresponding author). DR declare grants or contracts and royalties or licenses from Hitachi High-Technologies Corporation, Tokyo, Japan. DR is scientific board member of Eurofins company. DR is founder and shareholder of a microbial culture company (Culture Top), two biotechnology companies (Techno-jouvence, and Gene and Green TK), and a rapid diagnosis of infectious diseases company (Pocrame). All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Our group used widely available generic drugs distributed by many pharmaceutical companies.
This work was performed by academic doctors working in the IHU Mediterranee Infection. IHU Mediterranee Infection was funded by the French government and benefited from a grant from Agence Nationale de la Recherche: ANR-15-CE36-0004-01 and by ANR Investissements d avenir, Mediterranee infection 10-IAHU-03, and was also supported by Region Provence-Alpes-Cote d Azur.
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical committee of the Institut Hospitalo-Universitaire Mediterranee Infection gave ethical approval for this work (N: 2021-007 for outpatients and 2021-015 for inpatients).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
You’ll find the source for all of of Dr Ardis’ suggested supplements right below. You’ll find this video LIFE SAVING. Finally, someone who did the research, tested it, and came up with the solution.
- Vitamin C
- Apple Pectin powder
- Nicotine Patches (14 mg patches… then, cut them up into 2 mg squares (about 6 pieces) and use one every 24 hours)
- Additionally, you can add Ashuaghanda and Chased Tree (Vitax) Taking these together is what Dr Ardis said helps your body to make natural glutathione so that you won’t have to take that as well unless you want to.